Aldesleukin Completed Phase 2 Trials for Metastatic Melanoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00910650Study of Gene Modified Immune Cells in Patients With Advanced Melanoma
NCT00314106Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma